Search

Your search keyword '"Mura, Rosa Maria"' showing total 11 results
Start Over Author "Mura, Rosa Maria"
11 results on '"Mura, Rosa Maria"'

1. Epilepsy after acute central nervous system complications of pediatric hematopoietic cell transplantation: A retrospective, multicenter study

Author

Bergonzini, Luca, Leardini, Davide, Rao, Roberta, Foiadelli, Thomas, Faraci, Maura, Mancardi, Maria Margherita, Nobile, Giulia, Orsini, Alessandro, Savasta, Salvatore, Gottardi, Francesca, Fetta, Anna, Mina, Tommaso, Casazza, Gabriella, Menconi, Maria Cristina, Pruna, Dario, Mura, Rosa Maria, Piroddi, Antonio, Rucci, Paola, Masetti, Riccardo, and Cordelli, Duccio Maria

Published
2024
Full Text
View/download PDF

2. Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)

Author

Zama, Daniele, Baccelli, Francesco, Colombini, Antonella, Contino, Amalia, Calore, Elisabetta, Petris, Maria Grazia, Meneghello, Linda, Mercolini, Federico, Lo Vecchio, Andrea, Montalto, Shana, Meazza, Cristina, Barone, Angelica, Compagno, Francesca, Muggeo, Paola, Soncini, Elena, Brescia, Letizia, Giraldi, Eugenia, Giurici, Nagua, Mura, Rosa Maria, Cellini, Monica, Perruccio, Katia, Petroni, Valeria, La Spina, Milena, Ziino, Ottavio, Burnelli, Roberta, De Santis, Raffaella, Mascarin, Maurizio, Barretta, Valentina, Tridello, Gloria, and Cesaro, Simone

Published
2022
Full Text
View/download PDF

3. Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP Trial

Author

Prete, Arcangelo, Lanino, Edoardo, Saglio, Francesco, Biffi, Alessandra, Calore, Elisabetta, Faraci, Maura, Rondelli, Roberto, Favre, Claudio, Zecca, Marco, Casazza, Gabriella, Porta, Fulvio, Luksch, Roberto, Cesaro, Simone, Rabusin, Marco, Parasole, Rosanna, Mura, Rosa Maria, Lo Nigro, Luca, Leardini, Davide, Pagliara, Daria, Locatelli, Franco, and Fagioli, Franca

Published
2024
Full Text
View/download PDF

4. Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study

Author

Massano, Davide, primary, Carraro, Elisa, additional, Mussolin, Lara, additional, Buffardi, Salvatore, additional, Barat, Veronica, additional, Zama, Daniele, additional, Muggeo, Paola, additional, Vendemini, Francesca, additional, Sau, Antonella, additional, Moleti, Maria Luisa, additional, Verzegnassi, Federico, additional, D'Amico, Salvatore, additional, Casini, Tommaso, additional, Garaventa, Alberto, additional, Schiavello, Elisabetta, additional, Cellini, Monica, additional, Vinti, Luciana, additional, Farruggia, Piero, additional, Perruccio, Katia, additional, Cesaro, Simone, additional, De Santis, Raffaela, additional, Marinoni, Maddalena, additional, D'Alba, Irene, additional, Mura, Rosa Maria, additional, Burnelli, Roberta, additional, Mascarin, Maurizio, additional, and Pillon, Marta, additional

Published
2022
Full Text
View/download PDF

5. Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

Author

Garaventa, Alberto, primary, Parodi, Stefano, additional, Guerrini, Giulia, additional, Farruggia, Piero, additional, Sala, Alessandra, additional, Pillon, Marta, additional, Buffardi, Salvatore, additional, Rossi, Francesca, additional, Bianchi, Maurizio, additional, Zecca, Marco, additional, Vinti, Luciana, additional, Facchini, Elena, additional, Casini, Tommaso, additional, Bernasconi, Sayla, additional, Amoroso, Loredana, additional, D’Amico, Salvatore, additional, Provenzi, Massimo, additional, De Santis, Raffaela, additional, Sau, Antonella, additional, Muggeo, Paola, additional, Mura, Rosa Maria, additional, Haupt, Riccardo, additional, Mascarin, Maurizio, additional, and Burnelli, Roberta, additional

Published
2022
Full Text
View/download PDF

6. Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol

Author

Massimino, Maura, primary, Barretta, Francesco, additional, Modena, Piergiorgio, additional, Johann, Pascal, additional, Ferroli, Paolo, additional, Antonelli, Manila, additional, Gandola, Lorenza, additional, Garrè, Maria Luisa, additional, Bertin, Daniele, additional, Mastronuzzi, Angela, additional, Mascarin, Maurizio, additional, Quaglietta, Lucia, additional, Viscardi, Elisabetta, additional, Sardi, Iacopo, additional, Ruggiero, Antonio, additional, Boschetti, Luna, additional, Giagnacovo, Marzia, additional, Biassoni, Veronica, additional, Schiavello, Elisabetta, additional, Chiapparini, Luisa, additional, Erbetta, Alessandra, additional, Mussano, Anna, additional, Giussani, Carlo, additional, Mura, Rosa Maria, additional, Barra, Salvina, additional, Scarzello, Giovanni, additional, Scimone, Giuseppe, additional, Carai, Andrea, additional, Giangaspero, Felice, additional, and Buttarelli, Francesca Romana, additional

Published
2021
Full Text
View/download PDF

8. Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Author

Giona, Fiorina, primary, Saglio, Giuseppe, additional, Santopietro, Michelina, additional, Menna, Giuseppe, additional, Iaria, Grazia, additional, Putti, Maria Caterina, additional, Micalizzi, Concetta, additional, Santoro, Nicola, additional, Ladogana, Saverio, additional, Mura, Rosa Maria, additional, Burnelli, Roberta, additional, Consarino, Caterina, additional, Cosmi, Carlo, additional, Moleti, Maria Luisa, additional, Varotto, Stefania, additional, Tucci, Francesca, additional, Nanni, Mauro, additional, Diverio, Daniela, additional, Biondi, Andrea, additional, Locatelli, Franco, additional, and Foà, Robin, additional

Published
2015
Full Text
View/download PDF

9. Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)

Author

Daniele Zama, Francesco Baccelli, Antonella Colombini, Amalia Contino, Elisabetta Calore, Maria Grazia Petris, Linda Meneghello, Federico Mercolini, Andrea Lo Vecchio, Shana Montalto, Cristina Meazza, Angelica Barone, Francesca Compagno, Paola Muggeo, Elena Soncini, Letizia Brescia, Eugenia Giraldi, Nagua Giurici, Rosa Maria Mura, Monica Cellini, Katia Perruccio, Valeria Petroni, Milena La Spina, Ottavio Ziino, Roberta Burnelli, Raffaella De Santis, Maurizio Mascarin, Valentina Barretta, Gloria Tridello, Simone Cesaro, Zama, Daniele, Baccelli, Francesco, Colombini, Antonella, Contino, Amalia, Calore, Elisabetta, Petris, Maria Grazia, Meneghello, Linda, Mercolini, Federico, Lo Vecchio, Andrea, Montalto, Shana, Meazza, Cristina, Barone, Angelica, Compagno, Francesca, Muggeo, Paola, Soncini, Elena, Brescia, Letizia, Giraldi, Eugenia, Giurici, Nagua, Mura, Rosa Maria, Cellini, Monica, Perruccio, Katia, Petroni, Valeria, La Spina, Milena, Ziino, Ottavio, Burnelli, Roberta, De Santis, Raffaella, Mascarin, Maurizio, Barretta, Valentina, Tridello, Gloria, and Cesaro, Simone

Subjects
SARS-COV- 2 infection, SARS-CoV-2, COVID-19, Pediatric oncology, General Medicine, Hematology, Communicable Diseases, Italy, Neoplasms, Humans, RNA, Viral, Child, Children, Pandemics, Outcome
Abstract

COVID-19 has a mild clinical course with low mortality rate in general pediatric population, while variable outcomes have been described in children with cancer. Infectious diseases working party of the AIEOP collected data on the clinical characteristics and outcomes of SARS-CoV-2 infections in pediatric oncology/hematology patients from April 2020 to May 2021, including the second and the third waves of the pandemic in Italy. Factors potentially associated with moderate, severe, or critical COVID-19 were analyzed. Of the 153 SARS-Cov2 infections recorded, 100 were asymptomatic and 53 symptomatic. The course of COVID-19 was mild in 41, moderate in 2, severe in 5, and critical in 5 children. A total of 40.5% of patients were hospitalized, ten requiring oxygen support and 5 admitted to the intensive care unit. Antibiotics and steroids were the most used therapies. No patient died due to SARS-CoV-2 infection. Infections occurring early ( 60 days) or during maintenance therapy. In the patients on active chemotherapy, 59% withdrew the treatment for a median of 15 days. SARS-CoV-2 presented a favorable outcome in children with cancer in Italy during the pandemic. Modification of therapy represents a major concern in this population. Our findings suggest considering regular chemotherapy continuation, particularly in patients on maintenance therapy or infected late after the diagnosis.

Published
2022

10. TP53 DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.

Author

Martire G, Lovisa F, Carraro E, Rizzato D, Cesaro S, Mura RM, Tondo A, Bertolin C, Boaretto F, Salviati L, Biffi A, Pillon M, and Mussolin L

Subjects
Humans, Child, Prognosis, Male, Female, Child, Preschool, Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Rituximab therapeutic use, Burkitt Lymphoma genetics, Burkitt Lymphoma drug therapy, Burkitt Lymphoma mortality, Burkitt Lymphoma diagnosis, Mutation, Tumor Suppressor Protein p53 genetics
Published
2024
Full Text
View/download PDF

11. Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.

Author

Massimino M, Barretta F, Modena P, Johann P, Ferroli P, Antonelli M, Gandola L, Garrè ML, Bertin D, Mastronuzzi A, Mascarin M, Quaglietta L, Viscardi E, Sardi I, Ruggiero A, Boschetti L, Giagnacovo M, Biassoni V, Schiavello E, Chiapparini L, Erbetta A, Mussano A, Giussani C, Mura RM, Barra S, Scarzello G, Scimone G, Carai A, Giangaspero F, and Buttarelli FR

Subjects
Child, Preschool, Female, Humans, Neoplasm Recurrence, Local therapy, Prognosis, Treatment Outcome, Brain Neoplasms pathology, Ependymoma pathology
Abstract

Background: More than 40% of patients with intracranial ependymoma need a salvage treatment within 5 years after diagnosis, and no standard treatment is available as yet. We report the outcome after first relapse of 64 patients treated within the 2nd AIEOP protocol., Methods: We considered relapse sites and treatments, that is, various combinations of complete/incomplete surgery, if followed by standard or hypofractionated radiotherapy (RT) ± chemotherapy (CT). Molecular analyses were available for 38/64 samples obtained at first diagnosis. Of the 64 cases, 55 were suitable for subsequent analyses., Results: The median follow-up was 147 months after diagnosis, 84 months after first relapse, 5-year EFS/OS were 26.2%/30.8% (median EFS/OS 13/32 months) after relapse. For patients with a local relapse (LR), the 5-year cumulative incidence of second LRs was 51.6%, with a 5-year event-specific probability of being LR-free of 40.0%. Tumor site/grade, need for shunting, age above/below 3 years, molecular subgroup at diagnosis, had no influence on outcomes. Due to variation in the RT dose/fractionation used and the subgroup sizes, it was not possible to assess the impact of the different RT modalities. Multivariable analyses identified completion of surgery, the absence of symptoms at relapse, and female sex as prognostically favorable. Tumors with a 1q gain carried a higher cumulative incidence of dissemination after first relapse., Conclusions: Survival after recurrence was significantly influenced by symptoms and completeness of surgery. Only a homogeneous protocol with well-posed, randomized questions could clarify the numerous issues, orient salvage treatment, and ameliorate prognosis for this group of patients., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results